Profitability
This table shows how Spectral AI compares to its peers in net margins, return on equity, and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spectral AI | -89.85% | N/A | -104.64% |
| Competitors | -578.37% | -140.27% | -25.88% |
Ownership
67.1% of Spectral AI shares are owned by institutions, compared to 47.4% in the surgical instruments sector. Additionally, 56.7% are held by company insiders, against 15.9% for the sector. High institutional ownership suggests confidence in long-term growth.
Volatility & Risk
Spectral AI has a beta of 0.56, making it 44% less volatile than the S&P 500. Its competitors have a beta of 0.53, indicating similar stability.
Analyst Ratings
The following table summarizes recent ratings for Spectral AI and its peers:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spectral AI | 0 | 0 | 3 | 1 | 3.25 |
| Competitors | 1663 | 4406 | 8446 | 251 | 2.49 |
Spectral AI’s consensus target price is $4.50, indicating a potential upside of 265.85%, compared to 17.84% for its peers.
Valuation & Earnings
This table compares gross revenue, net income, and valuation of Spectral AI and its peers:
| Gross Revenue | Net Income | P/E Ratio | |
| Spectral AI | $18.06 million | -$20.85 million | -0.92 |
| Competitors | $870.57 million | $47.37 million | -1.16 |
Spectral AI has lower revenue and earnings compared to its peers but has a higher P/E ratio.
Summary
Spectral AI performs better than its peers on 10 out of 13 metrics analyzed.
Company Profile
Spectral AI develops AI-driven medical diagnostics in the U.S., focusing on wound care such as burns and diabetic ulcers. Key products include the DeepView System and DeepView SnapShot M, a portable diagnostic tool. The company is based in Dallas, Texas.
Receive News & Ratings – Enter your email to get daily updates on Spectral AI and related companies with MarketBeat.com’s FREE daily newsletter.
`
